2021 Allergic Reactions Anaphylaxis 
EMDocs
AUGUST 31, 2023
In April 2021, after a post-hoc analysis of the original phase 3 study suggested non-inferiority of the F(ab’) 2 antivenin against copperhead envenomation, the FDA expanded approval of this antivenom to include copperhead and cottonmouth envenomations. Published online April 2021. Ann Emerg Med. 2020;76(4):S29. Accessed May 7, 2022.
EMDocs
FEBRUARY 7, 2024
Hypersensitivity/dermatologic: GLP-1 agonists are synthetic peptides; may lead to antibody formation and allergic reaction/injection site reaction. Reactions are usually minor: transient warmth, pruritis at injection site that resolves. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.
RebelEM
AUGUST 3, 2023
What They Did: Parallel, 2-arm, noninferiority, open-label, multicenter, international randomized clinical trial Occurred in 6 specialized centers (3 in North America – US & Canada and 3 Outside of North America – Australia) Trial took place from June 2021 to December 2022 Used PEN-FAST to risk stratify patients.
Expert insights. Personalized for you.
97 
Let's personalize your content